GSK Biologicals Influenza Vaccine GSK576389A — Competitive Intelligence Brief

GSK Biologicals Influenza Vaccine GSK576389A (GSK Biologicals Influenza Vaccine GSK576389A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine. Area: Immunology.

phase 3 Influenza vaccine Immunology Biologic

Target snapshot

GSK Biologicals Influenza Vaccine GSK576389A (GSK Biologicals Influenza Vaccine GSK576389A) — GlaxoSmithKline. This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, providing protection against seasonal influenza infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GSK Biologicals Influenza Vaccine GSK576389A TARGET	GSK Biologicals Influenza Vaccine GSK576389A	GlaxoSmithKline	phase 3	Influenza vaccine
High Dose Trivalent Influenza Vaccine	High Dose Trivalent Influenza Vaccine	Brigham and Women's Hospital	marketed	Inactivated influenza vaccine
Influsplit SSW® 2005/2006	Influsplit SSW® 2005/2006	GlaxoSmithKline	marketed	Inactivated influenza vaccine
HD-TIV	HD-TIV	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Inactivated influenza vaccine
FluMist trivalent (2015-2016)	FluMist trivalent (2015-2016)	MedImmune LLC	marketed	Live attenuated influenza vaccine
Pandemic influenza A/H1N1 vaccine	Pandemic influenza A/H1N1 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
Prepandrix™	Prepandrix™	GlaxoSmithKline	marketed	Inactivated influenza vaccine	H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine class)

1. GlaxoSmithKline · 8 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
3. Seqirus · 2 drugs in this class
4. MedImmune LLC · 1 drug in this class
5. AstraZeneca · 1 drug in this class
6. Novartis · 1 drug in this class
7. Protein Sciences Corporation · 1 drug in this class
8. ModernaTX, Inc. · 1 drug in this class
9. Institute of Vaccines and Medical Biologicals, Vietnam · 1 drug in this class
10. Janssen Vaccines & Prevention B.V. · 1 drug in this class